Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Esketamine nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI), is the only treatment ...

Interest in the use of ketamine for the treatment of depression has risen in recent years. Two clinicians discussed the lessons they have learned in using ketamine and esketamine as adjunctive ...

A new study investigates how ketamine infusion affects different parts of the brain and could be an effective pharmaceutical ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Jeff Winograd, who's lived with depression for more than 25 years, says ketamine treatment saved his life. Jeff Winograd couldn’t get off his couch. He’d hit rock bottom with the depression he ...

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by an inadequate response to two or more oral antidepressants (OADs).

Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

Esketamine, a rapid-onset antidepressant, offers potential advantages for treatment-resistant depression, but its effect on women with perinatal depression is unknown.

If your depression doesn’t respond to treatment at first, you have other options. Learn more about therapies for treatment-resistant depression.